Stryker's Spine and Trauma & Extremities Divisions will be launching BIO4, its next generation viable bone matrix at the 2015 Annual Meeting of the American Academy of Orthopaedic Surgeons, March 24 to March 28 in Las Vegas.
BIO4 is a viable bone matrix containing endogenous bone forming cells and is intended to facilitate bone repair and regeneration. It aims at providing a safe alternative to bone autograft that minimizes the potential for harvest site co-morbidities.
"With the introduction of BIO4, Stryker now plays in the growing $199M Cellular Allograft Market," said Spencer Stiles, president of Stryker Spine.